Ovid Therapeutics Overview
- Founded
-
2014

- Status
-
Public
- Employees
-
44

- Stock Symbol
-
OVID

- Investments
-
1
- Share Price
-
$2.42
- (As of Wednesday Closing)
Ovid Therapeutics General Information
Description
Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life.
Contact Information
- 1460 Broadway
- Suite 15021
- New York, NY 10036
- United States
Ovid Therapeutics Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.42 | $2.50 | $1.41 - $3.55 | $176M | 70.5M | 88K | -$0.99 |
Ovid Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | (6,827) | 16,796 | 59,669 | 160,530 |
Revenue | 1,456 | 208,383 | 12,617 | 0 |
EBITDA | (68,015) | 124,400 | (80,729) | (60,206) |
Net Income | (68,664) | 122,835 | (81,036) | (60,461) |
Total Assets | 165,032 | 194,545 | 75,926 | 80,844 |
Total Debt | 16,249 |
Ovid Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Ovid Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Ovid Therapeutics Comparisons
Industry
Financing
Details
Ovid Therapeutics Competitors (14)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
CuraSen | Venture Capital-Backed | San Carlos, CA | 00 | 000.00 | 00000000000 | 000.00 |
000000000 00000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 00000000 | 000.00 |
000000000000 | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 00000000000 | |
0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
00000000 000000000 | Corporation | Coral Gables, FL | 00 | 000.00 | 00000000 | 000.00 |
Ovid Therapeutics Patents
Ovid Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020405060-A1 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
CA-3164635-A1 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
EP-4051272-A1 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
EP-4051272-A4 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
US-11364228-B2 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Active | 18-Dec-2019 | A61K31/437 | 00 |
Ovid Therapeutics Executive Team (15)
Ovid Therapeutics Board Members (8)
Name | Representing | Role | Since |
---|---|---|---|
Barbara Duncan | Ovid Therapeutics | Board Member | 000 0000 |
Bart Friedman JD | Self | Board Member | 000 0000 |
Jeremy Levin Ph.D | Ovid Therapeutics | Chief Executive Officer & Chairman | 000 0000 |
Karen Bernstein Ph.D | Self | Board Member | 000 0000 |
Kevin Fitzgerald | Ovid Therapeutics | Board Member | 000 0000 |
Ovid Therapeutics Signals
Ovid Therapeutics Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 | 06-Sep-2022 | 00000 0000 | 000 | Biotechnology | 000000 00 |
Ovid Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 12, 2019
29.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile

Pharmaceuticals
Industry
00 of 947
Rank
Percentile

Biotechnology
Subindustry
00 of 427
Rank
Percentile
